Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Crispr gets FDA orphan drug designation in T-Cell Lymphoma treatment » 18:04
06/15/21
06/15
18:04
06/15/21
18:04
CRSP

Crispr Therapeutics

$123.67 /

-5.14 (-3.99%)

The FDA granted Crispr…

The FDA granted Crispr Therapeutics orphan drug designation for its Cas9-mediated genetically modified CAR T cells targeting CD70 antigen in the treatment of T-cell Lymphoma. Reference Link

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$123.67 /

-5.14 (-3.99%)

CRSP Crispr Therapeutics
$123.67 /

-5.14 (-3.99%)

06/14/21
Fly Intel: Top five analyst upgrades
06/14/21 Citi
Crispr Therapeutics upgraded to Neutral from Sell at Citi
06/11/21 Roth Capital
Crispr Therapeutics reported 'robust' sickle cell data, says Roth Capital
05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
CRSP Crispr Therapeutics
$123.67 /

-5.14 (-3.99%)

  • 01
    Jul
CRSP Crispr Therapeutics
$123.67 /

-5.14 (-3.99%)

CRSP Crispr Therapeutics
$123.67 /

-5.14 (-3.99%)

Hot Stocks
Crispr Therapeutics announces strategic partnership with Capsida » 09:55
06/15/21
06/15
09:55
06/15/21
09:55
CRSP

Crispr Therapeutics

$126.50 /

-2.31 (-1.79%)

Crispr Therapeutics and…

Crispr Therapeutics and Capsida Biotherapeutics announced a strategic partnership to research, develop, manufacture and commercialize in vivo gene editing therapies delivered with engineered adeno-associated virus vectors for the treatment of familial amyotrophic lateral sclerosis and Friedreich's ataxia. Under the agreement, Crispr will lead research and development of the Friedreich's ataxia program and perform gene-editing activities for both programs, and Capsida will lead research and development of the ALS program and conduct capsid engineering for both programs. Crispr and Capsida will each have the option to co-develop and co-commercialize the program that the other company leads. Following such option, the companies would equally share all research, development and commercialization costs and profits worldwide related to the collaboration product. As part of the collaboration, Capsida will also be responsible for process development and clinical manufacture of both programs and have the option to manufacture commercial products generated under the agreement.

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$126.50 /

-2.31 (-1.79%)

CRSP Crispr Therapeutics
$126.50 /

-2.31 (-1.79%)

06/14/21
Fly Intel: Top five analyst upgrades
06/14/21 Citi
Crispr Therapeutics upgraded to Neutral from Sell at Citi
06/11/21 Roth Capital
Crispr Therapeutics reported 'robust' sickle cell data, says Roth Capital
05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
CRSP Crispr Therapeutics
$126.50 /

-2.31 (-1.79%)

  • 01
    Jul
CRSP Crispr Therapeutics
$126.50 /

-2.31 (-1.79%)

CRSP Crispr Therapeutics
$126.50 /

-2.31 (-1.79%)

Over a week ago
On The Fly
Wall Street in Fives - Must Read Lists for Monday » 16:07
06/14/21
06/14
16:07
06/14/21
16:07
RDS.A

Royal Dutch Shell

$41.18 /

+0.765 (+1.89%)

, RDS.B

Royal Dutch Shell

$39.02 /

+0.775 (+2.03%)

, NVAX

Novavax

$208.17 /

-1.43 (-0.68%)

, MRNA

Moderna

$206.41 /

-12.39 (-5.66%)

, RIDE

Lordstown Motors

$9.19 /

-2.215 (-19.43%)

, TSLA

Tesla

$616.40 /

+6.48 (+1.06%)

, WPG

Washington Prime

$3.35 /

-1.49 (-30.79%)

, CMG

Chipotle

$1,391.53 /

+24.24 (+1.77%)

, CRSP

Crispr Therapeutics

$128.44 /

+1.36 (+1.07%)

, OTLY

Oatly Group

$27.53 /

-1.18 (-4.11%)

, CLB

Core Laboratories

$45.25 /

-2.46 (-5.16%)

, AVB

AvalonBay

$213.71 /

-0.78 (-0.36%)

, VIVHY

Vivendi

$35.46 /

+0.39 (+1.11%)

, NGAC

NextGen Acquisition Corp.

$9.98 /

-0.02 (-0.20%)

, GSK

GlaxoSmithKline

$40.41 /

+0.26 (+0.65%)

, WOOF

Petco

$28.21 /

+4.4 (+18.48%)

, RAPT

Rapt Therapeutics

$40.40 /

+21.805 (+117.26%)

, ITOS

iTeos Therapeutics

$27.50 /

+7.5 (+37.50%)

, BTX

Brooklyn ImmunoTherapeutics

$15.16 /

+0.705 (+4.88%)

, ENDP

Endo

$5.63 /

-0.62 (-9.92%)

, FBIO

Fortress Biotech

$3.80 /

-0.69 (-15.37%)

, ATXI

Avenue Therapeutics

$2.95 /

-1.285 (-30.38%)

, MPAA

Motorcar Parts

$24.13 /

+0.89 (+3.83%)

, KLR

Kaleyra

$11.79 /

-0.61 (-4.92%)

, CANO

Cano Health

$14.80 /

+0.075 (+0.51%)

, CODA

Coda Octopus

$9.90 /

+0.75 (+8.20%)

, DUK

Duke Energy

$102.35 /

+0.42 (+0.41%)

, BTC

Bitcoin

$0.00 /

+ (+0.00%)

, BITCOIN

Bitcoin

/

+

, $BTC

Bitcoin

$0.00 /

+ (+0.00%)

Get caught up quickly on…

ShowHide Related Items >><<
WPG Washington Prime
$3.35 /

-1.49 (-30.79%)

WOOF Petco
$28.21 /

+4.4 (+18.48%)

VIVHY Vivendi
$35.46 /

+0.39 (+1.11%)

TSLA Tesla
$616.40 /

+6.48 (+1.06%)

RIDE Lordstown Motors
$9.19 /

-2.215 (-19.43%)

RDS.B Royal Dutch Shell
$39.02 /

+0.775 (+2.03%)

RDS.A Royal Dutch Shell
$41.18 /

+0.765 (+1.89%)

RAPT Rapt Therapeutics
$40.40 /

+21.805 (+117.26%)

NVAX Novavax
$208.17 /

-1.43 (-0.68%)

NGAC NextGen Acquisition Corp.
$9.98 /

-0.02 (-0.20%)

MRNA Moderna
$206.41 /

-12.39 (-5.66%)

MPAA Motorcar Parts
$24.13 /

+0.89 (+3.83%)

KLR Kaleyra
$11.79 /

-0.61 (-4.92%)

ITOS iTeos Therapeutics
$27.50 /

+7.5 (+37.50%)

GSK GlaxoSmithKline
$40.41 /

+0.26 (+0.65%)

FBIO Fortress Biotech
$3.80 /

-0.69 (-15.37%)

ENDP Endo
$5.63 /

-0.62 (-9.92%)

DUK Duke Energy
$102.35 /

+0.42 (+0.41%)

CRSP Crispr Therapeutics
$128.44 /

+1.36 (+1.07%)

CMG Chipotle
$1,391.53 /

+24.24 (+1.77%)

CLB Core Laboratories
$45.25 /

-2.46 (-5.16%)

CANO Cano Health
$14.80 /

+0.075 (+0.51%)

BTX Brooklyn ImmunoTherapeutics
$15.16 /

+0.705 (+4.88%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

BITCOIN Bitcoin
/

+

AVB AvalonBay
$213.71 /

-0.78 (-0.36%)

ATXI Avenue Therapeutics
$2.95 /

-1.285 (-30.38%)

RDS.A Royal Dutch Shell
$41.18 /

+0.765 (+1.89%)

06/08/21 DZ Bank
Royal Dutch Shell downgraded to Hold from Buy at DZ Bank
05/17/21 Mizuho
Royal Dutch Shell price target raised to $61 from $56 at Mizuho
04/30/21 Credit Suisse
Royal Dutch Shell price target raised to 1,860 GBp at Credit Suisse
04/20/21 Deutsche Bank
Royal Dutch Shell initiated with a Buy at Deutsche Bank
RDS.B Royal Dutch Shell
$39.02 /

+0.775 (+2.03%)

04/08/21 Barclays
Royal Dutch Shell price target raised to 1,700 GBp from 1,500 GBp at Barclays
03/12/21 Societe Generale
Royal Dutch Shell upgraded to Buy from Hold at Societe Generale
03/03/21 JPMorgan
Royal Dutch Shell price target raised to 2,000 GBp from 1,700 GBp at JPMorgan
02/12/21 Scotiabank
Royal Dutch Shell upgraded to Sector Perform from Underperform at Scotiabank
NVAX Novavax
$208.17 /

-1.43 (-0.68%)

06/07/21 B. Riley
Novavax risk/reward attractive into Covid vaccine data, says B. Riley
05/12/21
Fly Intel: Top five analyst downgrades
05/12/21 B. Riley
Novavax price target lowered to $286 from $365 at B. Riley
05/12/21 Cantor Fitzgerald
Novavax price target lowered to $217 from $338 at Cantor Fitzgerald
MRNA Moderna
$206.41 /

-12.39 (-5.66%)

06/10/21 Piper Sandler
Moderna should be vaccinating teens this summer, says Piper Sandler
06/07/21 Piper Sandler
Moderna price target raised to $246 from $231 at Piper Sandler
05/21/21 Piper Sandler
Piper says overseas approvals providing 'second leg of growth' for Moderna
05/07/21 Barclays
Moderna price target raised to $194 from $178 at Barclays
RIDE Lordstown Motors
$9.19 /

-2.215 (-19.43%)

06/14/21 Morgan Stanley
Lordstown management change 'important first step,' says Morgan Stanley
06/14/21 R.F. Lafferty
R.F. Lafferty downgrades Lordstown to Sell with $3 target on uncertainty
06/14/21 R.F. Lafferty
Lordstown Motors downgraded to Sell from Hold at R.F. Lafferty
06/10/21 Morgan Stanley
Morgan Stanley removes Lordstown rating, says market may be underestimating risk
TSLA Tesla
$616.40 /

+6.48 (+1.06%)

06/14/21 Canaccord
Tesla price target lowered to $812 from $974 at Canaccord
06/11/21 Credit Suisse
Tesla's Model S Plaid reinforces brand DNA, says Credit Suisse
06/11/21 Goldman Sachs
Goldman says Tesla's Model S Plaid helps illustrate technology leadership
06/08/21 GLJ Research
Tesla's China orders down 69% in Q2 versus Q1, says GLJ Research
WPG Washington Prime
$3.35 /

-1.49 (-30.79%)

04/06/21 Truist
Washington Prime upgraded to Hold from Sell at Truist
04/05/21 Truist
Washington Prime upgraded to Hold from Sell at Truist
02/16/21 Truist
Washington Prime coupon non-payment part of negotiating process, says Truist
02/01/21 Truist
Macerich Q4 results 'weak,' but not much worse than expected, says Truist
CMG Chipotle
$1,391.53 /

+24.24 (+1.77%)

06/14/21
Fly Intel: Top five analyst upgrades
06/14/21 Wells Fargo
Chipotle price target lowered to $1,720 from $1,818 at Wells Fargo
06/14/21 Raymond James
Raymond James upgrades Chipotle to Strong Buy on menu price hikes
06/14/21 Raymond James
Chipotle upgraded to Strong Buy from Outperform at Raymond James
CRSP Crispr Therapeutics
$128.44 /

+1.36 (+1.07%)

06/14/21 Citi
Crispr Therapeutics upgraded to Neutral from Sell at Citi
06/11/21 Roth Capital
Crispr Therapeutics reported 'robust' sickle cell data, says Roth Capital
05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
OTLY Oatly Group
$27.53 /

-1.18 (-4.11%)

06/14/21
Fly Intel: Top five analyst initiations
06/14/21 Jefferies
Oatly Group initiated with a Buy at Jefferies
06/14/21 JPMorgan
Oatly Group initiated with a Neutral at JPMorgan
06/14/21 Truist
Oatly Group initiated with a Buy at Truist
CLB Core Laboratories
$45.25 /

-2.46 (-5.16%)

06/14/21
Fly Intel: Top five analyst downgrades
06/14/21 Citi
Core Laboratories downgraded to Sell from Neutral at Citi
04/23/21 Citi
Core Laboratories price target lowered to $30 from $36 at Citi
01/11/21 Wolfe Research
Core Laboratories upgraded to Peer Perform from Underperform at Wolfe Research
AVB AvalonBay
$213.71 /

-0.78 (-0.36%)

06/14/21 Evercore ISI
AvalonBay downgraded to In Line from Outperform at Evercore ISI
06/11/21 Morgan Stanley
AvalonBay price target raised to $218 from $210 at Morgan Stanley
06/04/21 Truist
AvalonBay downgraded to Hold from Buy at Truist on premium valuation
VIVHY Vivendi
$35.46 /

+0.39 (+1.11%)

06/01/21
Fly Intel: Top five analyst downgrades
06/01/21 Bernstein
Vivendi downgraded to Market Perform from Outperform at Bernstein
05/14/21 Credit Suisse
Vivendi price target lowered to EUR 32.20 from EUR 32.40 at Credit Suisse
04/23/21 Barclays
Vivendi price target raised to EUR 32 from EUR 31 at Barclays
NGAC NextGen Acquisition Corp.
$9.98 /

-0.02 (-0.20%)

06/11/21 Benchmark
NextGen Acquisition Corp. initiated with a Buy at Benchmark
GSK GlaxoSmithKline
$40.41 /

+0.26 (+0.65%)

06/14/21 Piper Sandler
iTeos deal 'addresses a number of needs all at once, says Piper Sandler
06/11/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,300 GBp at Deutsche Bank
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
05/11/21 UBS
GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
WOOF Petco
$28.21 /

+4.4 (+18.48%)

06/02/21
Fly Intel: Top five analyst initiations
06/02/21 Citi
Petco reinstated with a Buy at Citi
05/21/21 Baird
Petco weakness a buying opportunity, says at Baird
05/20/21 Baird
Petco pullback a buying opportunity, says Baird
RAPT Rapt Therapeutics
$40.40 /

+21.805 (+117.26%)

06/14/21 Wells Fargo
Rapt Therapeutics price target raised to $65 from $30 at Wells Fargo
06/14/21 Roth Capital
Rapt Therapeutics price target raised to $72 from $38 at Roth Capital
06/14/21 Cantor Fitzgerald
Cantor ups Rapt target to $71 after 'robust' atopic dermatitis data
06/14/21 Cantor Fitzgerald
Rapt Therapeutics price target raised to $71 from $51 at Cantor Fitzgerald
ITOS iTeos Therapeutics
$27.50 /

+7.5 (+37.50%)

05/19/21 SVB Leerink
iTeos Therapeutics price target lowered to $45 from $60 at SVB Leerink
05/14/21 Piper Sandler
iTeos Therapeutics recent pullback unwarranted, says Piper Sandler
05/05/21 H.C. Wainwright
iTeos Therapeutics initiated with a Buy at H.C. Wainwright
BTX Brooklyn ImmunoTherapeutics
$15.16 /

+0.705 (+4.88%)

ENDP Endo
$5.63 /

-0.62 (-9.92%)

05/17/21 Citi
Endo price target raised to $11 from $10 at Citi
04/06/21 RBC Capital
Endo transferred with a Sector Perform at RBC Capital
03/08/21 Barclays
Endo price target raised to $7 from $6 at Barclays
03/04/21 Citi
Endo price target lowered to $10 from $11 at Citi
FBIO Fortress Biotech
$3.80 /

-0.69 (-15.37%)

04/14/21 B. Riley
Fortress Biotech weakness yesterday a buying opportunity, says B. Riley
04/05/21 B. Riley
Fortress Biotech price target raised to $9 from $8 at B. Riley
02/17/21 Dawson James
Fortress Biotech price target raised to $21 from $16 at Dawson James
12/14/20 Benchmark
Decision looms on Fortress' Caelum after partner Alexion bought, says Benchmark
ATXI Avenue Therapeutics
$2.95 /

-1.285 (-30.38%)

03/01/21 H.C. Wainwright
InvaGen takeout 'may still be in play' at Avenue, says H.C. Wainwright
10/12/20 H.C. Wainwright
Avenue downgraded to Neutral on merger uncertainty at H.C. Wainwright
MPAA Motorcar Parts
$24.13 /

+0.89 (+3.83%)

02/04/21 B. Riley
Motorcar Parts price target raised to $28 from $25 at B. Riley Securities
08/11/20 Craig-Hallum
Motorcar Parts downgraded to Hold from Buy at Craig-Hallum
07/01/20 B. Riley
Motorcar Parts transferred with Buy rating at B. Riley FBR
06/19/20 Roth Capital
Motorcar Parts assumed with a Buy at Roth Capital
KLR Kaleyra
$11.79 /

-0.61 (-4.92%)

06/11/21 Northland
Kaleyra price target raised to $29 from $23 at Northland
03/19/21 Northland
Kaleyra on track for 21% growth in Q1, says Northland
02/22/21 Maxim
Kaleyra price target raised to $42 from $30 at Maxim
02/17/21 Craig-Hallum
Kaleyra price target raised to $25 from $20 at Craig-Hallum
CANO Cano Health
$14.80 /

+0.075 (+0.51%)

11/19/20 Compass Point
Compass Point upgrades PennantPark to Buy after Cano Health 'game changer'
CODA Coda Octopus
$9.90 /

+0.75 (+8.20%)

06/14/21 Alliance Global Partners
Coda Octopus price target raised to $13 from $11 at Alliance Global
DUK Duke Energy
$102.35 /

+0.42 (+0.41%)

05/18/21 Morgan Stanley
Morgan Stanley sees 'low probability' Duke Energy and Elliott reach agreement
05/12/21 Mizuho
Duke Energy price target raised to $105 from $96 at Mizuho
04/14/21 Credit Suisse
Duke Energy price target raised to $104 from $96 at Credit Suisse
04/14/21 Wells Fargo
Duke Energy price target raised to $104 from $97 at Wells Fargo
BTC Bitcoin
$0.00 /

+ (+0.00%)

04/27/21 Roth Capital
Regulatory credits, bitcoin fuel Tesla Q1 headline beat, says Roth Capital
04/15/21 Morgan Stanley
WisdomTree Bitcoin ETP cross-listing could speed up growth, says Morgan Stanley
01/13/21 Standpoint Research
Bitcoin could hit $112,000 this year, says Standpoint Research
BITCOIN Bitcoin
/

+

05/13/21 BTIG
BTIG sees Binance news as 'net positive' for Coinbase
$BTC Bitcoin
$0.00 /

+ (+0.00%)

WPG Washington Prime
$3.35 /

-1.49 (-30.79%)

WOOF Petco
$28.21 /

+4.4 (+18.48%)

TSLA Tesla
$616.40 /

+6.48 (+1.06%)

RIDE Lordstown Motors
$9.19 /

-2.215 (-19.43%)

RDS.A Royal Dutch Shell
$41.18 /

+0.765 (+1.89%)

RAPT Rapt Therapeutics
$40.40 /

+21.805 (+117.26%)

NVAX Novavax
$208.17 /

-1.43 (-0.68%)

MRNA Moderna
$206.41 /

-12.39 (-5.66%)

MPAA Motorcar Parts
$24.13 /

+0.89 (+3.83%)

KLR Kaleyra
$11.79 /

-0.61 (-4.92%)

ITOS iTeos Therapeutics
$27.50 /

+7.5 (+37.50%)

GSK GlaxoSmithKline
$40.41 /

+0.26 (+0.65%)

FBIO Fortress Biotech
$3.80 /

-0.69 (-15.37%)

ENDP Endo
$5.63 /

-0.62 (-9.92%)

DUK Duke Energy
$102.35 /

+0.42 (+0.41%)

CRSP Crispr Therapeutics
$128.44 /

+1.36 (+1.07%)

CODA Coda Octopus
$9.90 /

+0.75 (+8.20%)

CMG Chipotle
$1,391.53 /

+24.24 (+1.77%)

CLB Core Laboratories
$45.25 /

-2.46 (-5.16%)

CANO Cano Health
$14.80 /

+0.075 (+0.51%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

AVB AvalonBay
$213.71 /

-0.78 (-0.36%)

  • 27
    May
  • 20
    May
  • 14
    Jan
  • 24
    Jul
  • 01
    Jul
  • 25
    Jun
WPG Washington Prime
$3.35 /

-1.49 (-30.79%)

WOOF Petco
$28.21 /

+4.4 (+18.48%)

VIVHY Vivendi
$35.46 /

+0.39 (+1.11%)

TSLA Tesla
$616.40 /

+6.48 (+1.06%)

RIDE Lordstown Motors
$9.19 /

-2.215 (-19.43%)

RDS.B Royal Dutch Shell
$39.02 /

+0.775 (+2.03%)

RDS.A Royal Dutch Shell
$41.18 /

+0.765 (+1.89%)

OTLY Oatly Group
$27.53 /

-1.18 (-4.11%)

NVAX Novavax
$208.17 /

-1.43 (-0.68%)

NGAC NextGen Acquisition Corp.
$9.98 /

-0.02 (-0.20%)

MRNA Moderna
$206.41 /

-12.39 (-5.66%)

GSK GlaxoSmithKline
$40.41 /

+0.26 (+0.65%)

ENDP Endo
$5.63 /

-0.62 (-9.92%)

DUK Duke Energy
$102.35 /

+0.42 (+0.41%)

CMG Chipotle
$1,391.53 /

+24.24 (+1.77%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

WOOF Petco
$28.21 /

+4.4 (+18.48%)

VIVHY Vivendi
$35.46 /

+0.39 (+1.11%)

TSLA Tesla
$616.40 /

+6.48 (+1.06%)

RIDE Lordstown Motors
$9.19 /

-2.215 (-19.43%)

RDS.B Royal Dutch Shell
$39.02 /

+0.775 (+2.03%)

RDS.A Royal Dutch Shell
$41.18 /

+0.765 (+1.89%)

OTLY Oatly Group
$27.53 /

-1.18 (-4.11%)

NVAX Novavax
$208.17 /

-1.43 (-0.68%)

NGAC NextGen Acquisition Corp.
$9.98 /

-0.02 (-0.20%)

MRNA Moderna
$206.41 /

-12.39 (-5.66%)

KLR Kaleyra
$11.79 /

-0.61 (-4.92%)

GSK GlaxoSmithKline
$40.41 /

+0.26 (+0.65%)

FBIO Fortress Biotech
$3.80 /

-0.69 (-15.37%)

ENDP Endo
$5.63 /

-0.62 (-9.92%)

DUK Duke Energy
$102.35 /

+0.42 (+0.41%)

CRSP Crispr Therapeutics
$128.44 /

+1.36 (+1.07%)

CMG Chipotle
$1,391.53 /

+24.24 (+1.77%)

CLB Core Laboratories
$45.25 /

-2.46 (-5.16%)

BTX Brooklyn ImmunoTherapeutics
$15.16 /

+0.705 (+4.88%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

ATXI Avenue Therapeutics
$2.95 /

-1.285 (-30.38%)

WPG Washington Prime
$3.35 /

-1.49 (-30.79%)

WOOF Petco
$28.21 /

+4.4 (+18.48%)

TSLA Tesla
$616.40 /

+6.48 (+1.06%)

RIDE Lordstown Motors
$9.19 /

-2.215 (-19.43%)

OTLY Oatly Group
$27.53 /

-1.18 (-4.11%)

NVAX Novavax
$208.17 /

-1.43 (-0.68%)

NGAC NextGen Acquisition Corp.
$9.98 /

-0.02 (-0.20%)

MRNA Moderna
$206.41 /

-12.39 (-5.66%)

KLR Kaleyra
$11.79 /

-0.61 (-4.92%)

GSK GlaxoSmithKline
$40.41 /

+0.26 (+0.65%)

FBIO Fortress Biotech
$3.80 /

-0.69 (-15.37%)

ENDP Endo
$5.63 /

-0.62 (-9.92%)

CRSP Crispr Therapeutics
$128.44 /

+1.36 (+1.07%)

CMG Chipotle
$1,391.53 /

+24.24 (+1.77%)

CANO Cano Health
$14.80 /

+0.075 (+0.51%)

BTX Brooklyn ImmunoTherapeutics
$15.16 /

+0.705 (+4.88%)

On The Fly
Wall Street in Fives - Must Read Lists at Midday » 12:02
06/14/21
06/14
12:02
06/14/21
12:02
NVAX

Novavax

$203.46 /

-6.14 (-2.93%)

, MRNA

Moderna

$205.25 /

-13.55 (-6.19%)

, RIDE

Lordstown Motors

$9.39 /

-2.01 (-17.63%)

, TSLA

Tesla

$616.70 /

+6.78 (+1.11%)

, WPG

Washington Prime

$3.71 /

-1.135 (-23.45%)

, CMG

Chipotle

$1,393.00 /

+25.71 (+1.88%)

, OTLY

Oatly Group

$27.64 /

-1.07 (-3.73%)

, CRSP

Crispr Therapeutics

$128.47 /

+1.39 (+1.09%)

, CLB

Core Laboratories

$47.61 /

-0.1 (-0.21%)

, AVB

AvalonBay

$212.92 /

-1.57 (-0.73%)

, VIVHY

Vivendi

$35.07 /

-0.13 (-0.37%)

, NGAC

NextGen Acquisition Corp.

$10.01 /

+0.01 (+0.10%)

, GSK

GlaxoSmithKline

$40.32 /

+0.17 (+0.42%)

, GS

Goldman Sachs

$373.62 /

-4.4 (-1.16%)

, RDS.A

Royal Dutch Shell

$41.47 /

+1.055 (+2.61%)

, RDS.B

Royal Dutch Shell

$39.26 /

+1.015 (+2.65%)

, RAPT

Rapt Therapeutics

$38.82 /

+20.225 (+108.77%)

, ITOS

iTeos Therapeutics

$27.55 /

+7.55 (+37.75%)

, BTX

Brooklyn ImmunoTherapeutics

$15.49 /

+1.04 (+7.20%)

, ENDP

Endo

$5.79 /

-0.46 (-7.36%)

, FBIO

Fortress Biotech

$3.94 /

-0.55 (-12.25%)

, BITCOIN

Bitcoin

/

+

, BTC

Bitcoin

/

+

, $BTC

Bitcoin

/

+

, MPAA

Motorcar Parts

$24.61 /

+1.37 (+5.90%)

, KLR

Kaleyra

$11.80 /

-0.6 (-4.84%)

, CANO

Cano Health

$15.02 /

+0.295 (+2.00%)

, CODA

Coda Octopus Group

$9.73 /

+0.58 (+6.34%)

, DUK

Duke Energy

$101.94 /

+0.01 (+0.01%)

1. STOCK NEWS: …

ShowHide Related Items >><<
WPG Washington Prime
$3.71 /

-1.135 (-23.45%)

VIVHY Vivendi
$35.07 /

-0.13 (-0.37%)

TSLA Tesla
$616.70 /

+6.78 (+1.11%)

RIDE Lordstown Motors
$9.39 /

-2.01 (-17.63%)

RDS.B Royal Dutch Shell
$39.26 /

+1.015 (+2.65%)

RDS.A Royal Dutch Shell
$41.47 /

+1.055 (+2.61%)

RAPT Rapt Therapeutics
$38.82 /

+20.225 (+108.77%)

NVAX Novavax
$203.46 /

-6.14 (-2.93%)

NGAC NextGen Acquisition Corp.
$10.01 /

+0.01 (+0.10%)

MRNA Moderna
$205.25 /

-13.55 (-6.19%)

MPAA Motorcar Parts
$24.61 /

+1.37 (+5.90%)

KLR Kaleyra
$11.80 /

-0.6 (-4.84%)

ITOS iTeos Therapeutics
$27.55 /

+7.55 (+37.75%)

GSK GlaxoSmithKline
$40.32 /

+0.17 (+0.42%)

GS Goldman Sachs
$373.62 /

-4.4 (-1.16%)

FBIO Fortress Biotech
$3.94 /

-0.55 (-12.25%)

ENDP Endo
$5.79 /

-0.46 (-7.36%)

DUK Duke Energy
$101.94 /

+0.01 (+0.01%)

CRSP Crispr Therapeutics
$128.47 /

+1.39 (+1.09%)

CMG Chipotle
$1,393.00 /

+25.71 (+1.88%)

CLB Core Laboratories
$47.61 /

-0.1 (-0.21%)

CANO Cano Health
$15.02 /

+0.295 (+2.00%)

BTX Brooklyn ImmunoTherapeutics
$15.49 /

+1.04 (+7.20%)

BTC Bitcoin
/

+

BITCOIN Bitcoin
/

+

AVB AvalonBay
$212.92 /

-1.57 (-0.73%)

NVAX Novavax
$203.46 /

-6.14 (-2.93%)

06/07/21 B. Riley
Novavax risk/reward attractive into Covid vaccine data, says B. Riley
05/12/21
Fly Intel: Top five analyst downgrades
05/12/21 B. Riley
Novavax price target lowered to $286 from $365 at B. Riley
05/12/21 Cantor Fitzgerald
Novavax price target lowered to $217 from $338 at Cantor Fitzgerald
MRNA Moderna
$205.25 /

-13.55 (-6.19%)

06/10/21 Piper Sandler
Moderna should be vaccinating teens this summer, says Piper Sandler
06/07/21 Piper Sandler
Moderna price target raised to $246 from $231 at Piper Sandler
05/21/21 Piper Sandler
Piper says overseas approvals providing 'second leg of growth' for Moderna
05/07/21 Barclays
Moderna price target raised to $194 from $178 at Barclays
RIDE Lordstown Motors
$9.39 /

-2.01 (-17.63%)

06/14/21 R.F. Lafferty
R.F. Lafferty downgrades Lordstown to Sell with $3 target on uncertainty
06/14/21 R.F. Lafferty
Lordstown Motors downgraded to Sell from Hold at R.F. Lafferty
06/10/21 Morgan Stanley
Morgan Stanley removes Lordstown rating, says market may be underestimating risk
06/08/21 RBC Capital
Lordstown Motors initiated with an Underperform at RBC Capital
TSLA Tesla
$616.70 /

+6.78 (+1.11%)

06/14/21 Canaccord
Tesla price target lowered to $812 from $974 at Canaccord
06/11/21 Credit Suisse
Tesla's Model S Plaid reinforces brand DNA, says Credit Suisse
06/11/21 Goldman Sachs
Goldman says Tesla's Model S Plaid helps illustrate technology leadership
06/08/21 GLJ Research
Tesla's China orders down 69% in Q2 versus Q1, says GLJ Research
WPG Washington Prime
$3.71 /

-1.135 (-23.45%)

04/06/21 Truist
Washington Prime upgraded to Hold from Sell at Truist
04/05/21 Truist
Washington Prime upgraded to Hold from Sell at Truist
02/16/21 Truist
Washington Prime coupon non-payment part of negotiating process, says Truist
02/01/21 Truist
Macerich Q4 results 'weak,' but not much worse than expected, says Truist
CMG Chipotle
$1,393.00 /

+25.71 (+1.88%)

06/14/21
Fly Intel: Top five analyst upgrades
06/14/21 Wells Fargo
Chipotle price target lowered to $1,720 from $1,818 at Wells Fargo
06/14/21 Raymond James
Raymond James upgrades Chipotle to Strong Buy on menu price hikes
06/14/21 Raymond James
Chipotle upgraded to Strong Buy from Outperform at Raymond James
OTLY Oatly Group
$27.64 /

-1.07 (-3.73%)

06/14/21
Fly Intel: Top five analyst initiations
06/14/21 Jefferies
Oatly Group initiated with a Buy at Jefferies
06/14/21 JPMorgan
Oatly Group initiated with a Neutral at JPMorgan
06/14/21 Truist
Oatly Group initiated with a Buy at Truist
CRSP Crispr Therapeutics
$128.47 /

+1.39 (+1.09%)

06/14/21 Citi
Crispr Therapeutics upgraded to Neutral from Sell at Citi
06/11/21 Roth Capital
Crispr Therapeutics reported 'robust' sickle cell data, says Roth Capital
05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
CLB Core Laboratories
$47.61 /

-0.1 (-0.21%)

06/14/21
Fly Intel: Top five analyst downgrades
06/14/21 Citi
Core Laboratories downgraded to Sell from Neutral at Citi
04/23/21 Citi
Core Laboratories price target lowered to $30 from $36 at Citi
01/11/21 Wolfe Research
Core Laboratories upgraded to Peer Perform from Underperform at Wolfe Research
AVB AvalonBay
$212.92 /

-1.57 (-0.73%)

06/14/21 Evercore ISI
AvalonBay downgraded to In Line from Outperform at Evercore ISI
06/11/21 Morgan Stanley
AvalonBay price target raised to $218 from $210 at Morgan Stanley
06/04/21 Truist
AvalonBay downgraded to Hold from Buy at Truist on premium valuation
VIVHY Vivendi
$35.07 /

-0.13 (-0.37%)

06/01/21
Fly Intel: Top five analyst downgrades
06/01/21 Bernstein
Vivendi downgraded to Market Perform from Outperform at Bernstein
05/14/21 Credit Suisse
Vivendi price target lowered to EUR 32.20 from EUR 32.40 at Credit Suisse
04/23/21 Barclays
Vivendi price target raised to EUR 32 from EUR 31 at Barclays
NGAC NextGen Acquisition Corp.
$10.01 /

+0.01 (+0.10%)

06/11/21 Benchmark
NextGen Acquisition Corp. initiated with a Buy at Benchmark
GSK GlaxoSmithKline
$40.32 /

+0.17 (+0.42%)

06/14/21 Piper Sandler
iTeos deal 'addresses a number of needs all at once, says Piper Sandler
06/11/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,300 GBp at Deutsche Bank
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
05/11/21 UBS
GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
GS Goldman Sachs
$373.62 /

-4.4 (-1.16%)

06/09/21 Jefferies
Jefferies starts 'too cheap' Goldman Sachs at Buy
06/09/21 Jefferies
Goldman Sachs initiated with a Buy at Jefferies
06/01/21 Piper Sandler
Goldman Sachs price target raised to $420 from $385 at Piper Sandler
05/12/21 Wells Fargo
Summer travel should be catalyst for commercial aero, says Wells Fargo
RDS.A Royal Dutch Shell
$41.47 /

+1.055 (+2.61%)

06/08/21 DZ Bank
Royal Dutch Shell downgraded to Hold from Buy at DZ Bank
05/17/21 Mizuho
Royal Dutch Shell price target raised to $61 from $56 at Mizuho
04/30/21 Credit Suisse
Royal Dutch Shell price target raised to 1,860 GBp at Credit Suisse
04/20/21 Deutsche Bank
Royal Dutch Shell initiated with a Buy at Deutsche Bank
RDS.B Royal Dutch Shell
$39.26 /

+1.015 (+2.65%)

04/08/21 Barclays
Royal Dutch Shell price target raised to 1,700 GBp from 1,500 GBp at Barclays
03/12/21 Societe Generale
Royal Dutch Shell upgraded to Buy from Hold at Societe Generale
03/03/21 JPMorgan
Royal Dutch Shell price target raised to 2,000 GBp from 1,700 GBp at JPMorgan
02/12/21 Scotiabank
Royal Dutch Shell upgraded to Sector Perform from Underperform at Scotiabank
RAPT Rapt Therapeutics
$38.82 /

+20.225 (+108.77%)

06/14/21 Cantor Fitzgerald
Cantor ups Rapt target to $71 after 'robust' atopic dermatitis data
06/14/21 Cantor Fitzgerald
Rapt Therapeutics price target raised to $71 from $51 at Cantor Fitzgerald
05/17/21 H.C. Wainwright
Rapt Therapeutics price target lowered to $29 from $32 at H.C. Wainwright
04/12/21 Roth Capital
Roth says Rapt Therapeutics' AACR presentations highlight broad potential
ITOS iTeos Therapeutics
$27.55 /

+7.55 (+37.75%)

05/19/21 SVB Leerink
iTeos Therapeutics price target lowered to $45 from $60 at SVB Leerink
05/14/21 Piper Sandler
iTeos Therapeutics recent pullback unwarranted, says Piper Sandler
05/05/21 H.C. Wainwright
iTeos Therapeutics initiated with a Buy at H.C. Wainwright
BTX Brooklyn ImmunoTherapeutics
$15.49 /

+1.04 (+7.20%)

ENDP Endo
$5.79 /

-0.46 (-7.36%)

05/17/21 Citi
Endo price target raised to $11 from $10 at Citi
04/06/21 RBC Capital
Endo transferred with a Sector Perform at RBC Capital
03/08/21 Barclays
Endo price target raised to $7 from $6 at Barclays
03/04/21 Citi
Endo price target lowered to $10 from $11 at Citi
FBIO Fortress Biotech
$3.94 /

-0.55 (-12.25%)

04/14/21 B. Riley
Fortress Biotech weakness yesterday a buying opportunity, says B. Riley
04/05/21 B. Riley
Fortress Biotech price target raised to $9 from $8 at B. Riley
02/17/21 Dawson James
Fortress Biotech price target raised to $21 from $16 at Dawson James
12/14/20 Benchmark
Decision looms on Fortress' Caelum after partner Alexion bought, says Benchmark
BITCOIN Bitcoin
/

+

05/13/21 BTIG
BTIG sees Binance news as 'net positive' for Coinbase
04/27/21 Roth Capital
Regulatory credits, bitcoin fuel Tesla Q1 headline beat, says Roth Capital
04/15/21 Morgan Stanley
WisdomTree Bitcoin ETP cross-listing could speed up growth, says Morgan Stanley
BTC Bitcoin
/

+

01/13/21 Standpoint Research
Bitcoin could hit $112,000 this year, says Standpoint Research
$BTC Bitcoin
/

+

MPAA Motorcar Parts
$24.61 /

+1.37 (+5.90%)

02/04/21 B. Riley
Motorcar Parts price target raised to $28 from $25 at B. Riley Securities
08/11/20 Craig-Hallum
Motorcar Parts downgraded to Hold from Buy at Craig-Hallum
07/01/20 B. Riley
Motorcar Parts transferred with Buy rating at B. Riley FBR
06/19/20 Roth Capital
Motorcar Parts assumed with a Buy at Roth Capital
KLR Kaleyra
$11.80 /

-0.6 (-4.84%)

06/11/21 Northland
Kaleyra price target raised to $29 from $23 at Northland
03/19/21 Northland
Kaleyra on track for 21% growth in Q1, says Northland
02/22/21 Maxim
Kaleyra price target raised to $42 from $30 at Maxim
02/17/21 Craig-Hallum
Kaleyra price target raised to $25 from $20 at Craig-Hallum
CANO Cano Health
$15.02 /

+0.295 (+2.00%)

11/19/20 Compass Point
Compass Point upgrades PennantPark to Buy after Cano Health 'game changer'
CODA Coda Octopus Group
$9.73 /

+0.58 (+6.34%)

DUK Duke Energy
$101.94 /

+0.01 (+0.01%)

05/18/21 Morgan Stanley
Morgan Stanley sees 'low probability' Duke Energy and Elliott reach agreement
05/12/21 Mizuho
Duke Energy price target raised to $105 from $96 at Mizuho
04/14/21 Credit Suisse
Duke Energy price target raised to $104 from $96 at Credit Suisse
04/14/21 Wells Fargo
Duke Energy price target raised to $104 from $97 at Wells Fargo
WPG Washington Prime
$3.71 /

-1.135 (-23.45%)

TSLA Tesla
$616.70 /

+6.78 (+1.11%)

RIDE Lordstown Motors
$9.39 /

-2.01 (-17.63%)

RDS.A Royal Dutch Shell
$41.47 /

+1.055 (+2.61%)

RAPT Rapt Therapeutics
$38.82 /

+20.225 (+108.77%)

NVAX Novavax
$203.46 /

-6.14 (-2.93%)

MRNA Moderna
$205.25 /

-13.55 (-6.19%)

MPAA Motorcar Parts
$24.61 /

+1.37 (+5.90%)

KLR Kaleyra
$11.80 /

-0.6 (-4.84%)

ITOS iTeos Therapeutics
$27.55 /

+7.55 (+37.75%)

GSK GlaxoSmithKline
$40.32 /

+0.17 (+0.42%)

GS Goldman Sachs
$373.62 /

-4.4 (-1.16%)

FBIO Fortress Biotech
$3.94 /

-0.55 (-12.25%)

ENDP Endo
$5.79 /

-0.46 (-7.36%)

DUK Duke Energy
$101.94 /

+0.01 (+0.01%)

CRSP Crispr Therapeutics
$128.47 /

+1.39 (+1.09%)

CODA Coda Octopus Group
$9.73 /

+0.58 (+6.34%)

CMG Chipotle
$1,393.00 /

+25.71 (+1.88%)

CLB Core Laboratories
$47.61 /

-0.1 (-0.21%)

CANO Cano Health
$15.02 /

+0.295 (+2.00%)

BITCOIN Bitcoin
/

+

AVB AvalonBay
$212.92 /

-1.57 (-0.73%)

  • 20
    May
  • 24
    Jul
  • 01
    Jul
  • 25
    Jun
WPG Washington Prime
$3.71 /

-1.135 (-23.45%)

VIVHY Vivendi
$35.07 /

-0.13 (-0.37%)

TSLA Tesla
$616.70 /

+6.78 (+1.11%)

RIDE Lordstown Motors
$9.39 /

-2.01 (-17.63%)

RDS.B Royal Dutch Shell
$39.26 /

+1.015 (+2.65%)

RDS.A Royal Dutch Shell
$41.47 /

+1.055 (+2.61%)

OTLY Oatly Group
$27.64 /

-1.07 (-3.73%)

NVAX Novavax
$203.46 /

-6.14 (-2.93%)

NGAC NextGen Acquisition Corp.
$10.01 /

+0.01 (+0.10%)

MRNA Moderna
$205.25 /

-13.55 (-6.19%)

GSK GlaxoSmithKline
$40.32 /

+0.17 (+0.42%)

GS Goldman Sachs
$373.62 /

-4.4 (-1.16%)

ENDP Endo
$5.79 /

-0.46 (-7.36%)

DUK Duke Energy
$101.94 /

+0.01 (+0.01%)

CMG Chipotle
$1,393.00 /

+25.71 (+1.88%)

BITCOIN Bitcoin
/

+

VIVHY Vivendi
$35.07 /

-0.13 (-0.37%)

TSLA Tesla
$616.70 /

+6.78 (+1.11%)

RIDE Lordstown Motors
$9.39 /

-2.01 (-17.63%)

RDS.B Royal Dutch Shell
$39.26 /

+1.015 (+2.65%)

RDS.A Royal Dutch Shell
$41.47 /

+1.055 (+2.61%)

OTLY Oatly Group
$27.64 /

-1.07 (-3.73%)

NVAX Novavax
$203.46 /

-6.14 (-2.93%)

NGAC NextGen Acquisition Corp.
$10.01 /

+0.01 (+0.10%)

MRNA Moderna
$205.25 /

-13.55 (-6.19%)

KLR Kaleyra
$11.80 /

-0.6 (-4.84%)

GSK GlaxoSmithKline
$40.32 /

+0.17 (+0.42%)

GS Goldman Sachs
$373.62 /

-4.4 (-1.16%)

FBIO Fortress Biotech
$3.94 /

-0.55 (-12.25%)

ENDP Endo
$5.79 /

-0.46 (-7.36%)

DUK Duke Energy
$101.94 /

+0.01 (+0.01%)

CRSP Crispr Therapeutics
$128.47 /

+1.39 (+1.09%)

CMG Chipotle
$1,393.00 /

+25.71 (+1.88%)

CLB Core Laboratories
$47.61 /

-0.1 (-0.21%)

BTX Brooklyn ImmunoTherapeutics
$15.49 /

+1.04 (+7.20%)

BITCOIN Bitcoin
/

+

WPG Washington Prime
$3.71 /

-1.135 (-23.45%)

TSLA Tesla
$616.70 /

+6.78 (+1.11%)

RIDE Lordstown Motors
$9.39 /

-2.01 (-17.63%)

OTLY Oatly Group
$27.64 /

-1.07 (-3.73%)

NVAX Novavax
$203.46 /

-6.14 (-2.93%)

NGAC NextGen Acquisition Corp.
$10.01 /

+0.01 (+0.10%)

MRNA Moderna
$205.25 /

-13.55 (-6.19%)

KLR Kaleyra
$11.80 /

-0.6 (-4.84%)

GSK GlaxoSmithKline
$40.32 /

+0.17 (+0.42%)

GS Goldman Sachs
$373.62 /

-4.4 (-1.16%)

FBIO Fortress Biotech
$3.94 /

-0.55 (-12.25%)

ENDP Endo
$5.79 /

-0.46 (-7.36%)

CRSP Crispr Therapeutics
$128.47 /

+1.39 (+1.09%)

CMG Chipotle
$1,393.00 /

+25.71 (+1.88%)

CANO Cano Health
$15.02 /

+0.295 (+2.00%)

BTX Brooklyn ImmunoTherapeutics
$15.49 /

+1.04 (+7.20%)

Upgrade
Fly Intel: Top five analyst upgrades » 09:53
06/14/21
06/14
09:53
06/14/21
09:53
CMG

Chipotle

$1,394.00 /

+26.71 (+1.95%)

, CRSP

Crispr Therapeutics

$129.20 /

+2.12 (+1.67%)

, WEN

Wendy's

$24.71 /

+0.58 (+2.40%)

, WELL

Welltower

$80.01 /

+0.49 (+0.62%)

, CQP

Cheniere Energy Partners

$43.99 /

+0.79 (+1.83%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chipotle (CMG) upgraded to Strong Buy from Outperform at Raymond James with analyst Brian Vaccaro saying the recently announced menu price increases of 4% in recent weeks with more coming in the fall create "significant upside" to second half of 2021 consensus comp expectations. 2. Crispr Therapeutics (CRSP) upgraded to Neutral from Sell at Citi with analyst Yigal Nochomovitz saying it is becoming increasingly clear that CTX001 is demonstrating consistent durable increases in fetal hemoglobin that are yielding prolonged therapeutic benefit on transfusion-independence in beta-thalassemia and freedom from vaso-occlusive crisis in sickle-cell. 3. Wendy's (WEN) upgraded to Buy from Neutral at Northcoast with analyst Jim Sanderson saying channel checks are "just as compelling as ever" and indicate that Wendy's current performance is exceeding expectations. 4. Welltower (WELL) upgraded to Outperform from In Line at Evercore ISI with analyst Steve Sakwa citing improving SH operations, a better acquisition outlook and the potential for long-term margin expansion with the recent hiring of John Burkart. 5. Cheniere Energy Partners (CQP) upgraded to Buy from Neutral at Goldman Sachs with analyst Michael Lapides citing recent underperformance, its defensive and largely contracted asset base that offers visibility into stable cash flows and upside to consensus from tailwinds to Cheniere Energy Partners' commodity margins from global natural gas prices. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
WEN Wendy's
$24.71 /

+0.58 (+2.40%)

WELL Welltower
$80.01 /

+0.49 (+0.62%)

CRSP Crispr Therapeutics
$129.20 /

+2.12 (+1.67%)

CQP Cheniere Energy Partners
$43.99 /

+0.79 (+1.83%)

CMG Chipotle
$1,394.00 /

+26.71 (+1.95%)

CMG Chipotle
$1,394.00 /

+26.71 (+1.95%)

06/14/21 Wells Fargo
Chipotle price target lowered to $1,720 from $1,818 at Wells Fargo
06/14/21 Raymond James
Raymond James upgrades Chipotle to Strong Buy on menu price hikes
06/14/21 Raymond James
Chipotle upgraded to Strong Buy from Outperform at Raymond James
06/07/21 Piper Sandler
Chipotle reiterated as top pick for 2021 at Piper Sandler
CRSP Crispr Therapeutics
$129.20 /

+2.12 (+1.67%)

06/14/21 Citi
Crispr Therapeutics upgraded to Neutral from Sell at Citi
06/11/21 Roth Capital
Crispr Therapeutics reported 'robust' sickle cell data, says Roth Capital
05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
04/21/21 Jefferies
Jefferies upgrades Crispr Therapeutics to Buy after Vertex deal renegotiated
WEN Wendy's
$24.71 /

+0.58 (+2.40%)

06/14/21 Northcoast
Wendy's upgraded to Buy from Neutral at Northcoast
06/14/21 Piper Sandler
Wendy's estimates raised on increasing momentum at Piper Sandler
06/09/21 Northcoast
Wendy's downgraded to Neutral from Buy at Northcoast
06/09/21
Fly Intel: Top five analyst downgrades
WELL Welltower
$80.01 /

+0.49 (+0.62%)

06/14/21 Evercore ISI
Welltower upgraded to Outperform from In Line at Evercore ISI
06/03/21 Deutsche Bank
Welltower price target raised to $80 from $76 at Deutsche Bank
05/21/21 Capital One
Welltower upgraded to Overweight from Equalweight at Capital One
05/04/21 Wells Fargo
Welltower price target raised to $78 from $71 at Wells Fargo
CQP Cheniere Energy Partners
$43.99 /

+0.79 (+1.83%)

06/13/21 Goldman Sachs
Cheniere Energy Partners upgraded to Buy from Neutral at Goldman Sachs
03/12/21
Fly Intel: Top five analyst downgrades
03/12/21 JPMorgan
Cheniere Energy Partners downgraded to Underweight from Neutral at JPMorgan
02/01/21 Scotiabank
Cheniere Energy Partners downgraded to Sector Perform from Outperform at Scotiabank
WEN Wendy's
$24.71 /

+0.58 (+2.40%)

WELL Welltower
$80.01 /

+0.49 (+0.62%)

CRSP Crispr Therapeutics
$129.20 /

+2.12 (+1.67%)

CQP Cheniere Energy Partners
$43.99 /

+0.79 (+1.83%)

CMG Chipotle
$1,394.00 /

+26.71 (+1.95%)

  • 01
    Jul
WEN Wendy's
$24.71 /

+0.58 (+2.40%)

CMG Chipotle
$1,394.00 /

+26.71 (+1.95%)

WEN Wendy's
$24.71 /

+0.58 (+2.40%)

CRSP Crispr Therapeutics
$129.20 /

+2.12 (+1.67%)

CQP Cheniere Energy Partners
$43.99 /

+0.79 (+1.83%)

CMG Chipotle
$1,394.00 /

+26.71 (+1.95%)

WEN Wendy's
$24.71 /

+0.58 (+2.40%)

WELL Welltower
$80.01 /

+0.49 (+0.62%)

CRSP Crispr Therapeutics
$129.20 /

+2.12 (+1.67%)

CMG Chipotle
$1,394.00 /

+26.71 (+1.95%)

Upgrade
Crispr Therapeutics upgraded to Neutral from Sell at Citi » 05:57
06/14/21
06/14
05:57
06/14/21
05:57
CRSP

Crispr Therapeutics

$127.08 /

+3.41 (+2.76%)

Citi analyst Yigal…

Citi analyst Yigal Nochomovitz upgraded Crispr Therapeutics to Neutral from Sell with a price target of $132, up from $55. It is becoming increasingly clear that CTX001 is demonstrating consistent durable increases in fetal hemoglobin that are yielding prolonged therapeutic benefit on transfusion-independence in beta-thalassemia and freedom from vaso-occlusive crisis in sickle-cell, Nochomovitz tells investors in a research note. As such, the analyst upwardly revise his valuation assumptions to reflect "lower risk to future revenues."

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$127.08 /

+3.41 (+2.76%)

CRSP Crispr Therapeutics
$127.08 /

+3.41 (+2.76%)

06/11/21 Roth Capital
Crispr Therapeutics reported 'robust' sickle cell data, says Roth Capital
05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
04/21/21 Jefferies
Jefferies upgrades Crispr Therapeutics to Buy after Vertex deal renegotiated
04/21/21 Barclays
Crispr Therapeutics price target raised to $160 from $140 at Barclays
CRSP Crispr Therapeutics
$127.08 /

+3.41 (+2.76%)

  • 01
    Jul
CRSP Crispr Therapeutics
$127.08 /

+3.41 (+2.76%)

CRSP Crispr Therapeutics
$127.08 /

+3.41 (+2.76%)

Recommendations
Crispr Therapeutics reported 'robust' sickle cell data, says Roth Capital » 10:45
06/11/21
06/11
10:45
06/11/21
10:45
CRSP

Crispr Therapeutics

$127.13 /

+3.46 (+2.80%)

, VRTX

Vertex Pharmaceuticals

$197.88 /

-19.07 (-8.79%)

Crispr Therapeutics…

Crispr Therapeutics (CSRP) provided "robust" updated data from its bone marrow editing program for a functional cure for sickle cell disease and transfusion-dependent thalassemia, Roth Capital analyst Tony Butler tells investors in a research note. The program is the subject of a partnership between Crispr and Vertex Pharmaceuticals (VRTX). The data show "rapid and consistent" symptom relief with persistent hemoglobin production, says the analyst. Further, Butler says the safety data from all 22 patients were generally consistent with an autologous stem cell transplant and myeloablative conditioning. He keeps a Buy rating on Crispr shares with a $171 price target. The stock in morning trading is up 2%, or $2.79, to $126.50.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$197.88 /

-19.07 (-8.79%)

CRSP Crispr Therapeutics
$127.13 /

+3.46 (+2.80%)

CRSP Crispr Therapeutics
$127.13 /

+3.46 (+2.80%)

05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
04/21/21 Jefferies
Jefferies upgrades Crispr Therapeutics to Buy after Vertex deal renegotiated
04/21/21 Barclays
Crispr Therapeutics price target raised to $160 from $140 at Barclays
04/21/21 Jefferies
Crispr Therapeutics upgraded to Buy from Hold at Jefferies
VRTX Vertex Pharmaceuticals
$197.88 /

-19.07 (-8.79%)

06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 Stifel
Vertex shares look 'cheap' at aftermarket levels, says Stifel
06/11/21 Cantor Fitzgerald
Vertex Pharmaceuticals price target lowered to $281 from $285 at Cantor Fitzgerald
06/11/21 Goldman Sachs
Vertex trading below cystic fibrosis franchise value, says Goldman Sachs
VRTX Vertex Pharmaceuticals
$197.88 /

-19.07 (-8.79%)

CRSP Crispr Therapeutics
$127.13 /

+3.46 (+2.80%)

  • 01
    Jul
VRTX Vertex Pharmaceuticals
$197.88 /

-19.07 (-8.79%)

VRTX Vertex Pharmaceuticals
$197.88 /

-19.07 (-8.79%)

CRSP Crispr Therapeutics
$127.13 /

+3.46 (+2.80%)

VRTX Vertex Pharmaceuticals
$197.88 /

-19.07 (-8.79%)

CRSP Crispr Therapeutics
$127.13 /

+3.46 (+2.80%)

Hot Stocks
Vertex Pharmaceuticals, Crispr Therapeutics announce new CTX001 data » 05:18
06/11/21
06/11
05:18
06/11/21
05:18
VRTX

Vertex Pharmaceuticals

$216.92 /

+3.43 (+1.61%)

, CRSP

Crispr Therapeutics

$123.67 /

+3.69 (+3.08%)

Vertex Pharmaceuticals…

Vertex Pharmaceuticals (VRTX) and Crispr Therapeutics (CRSP) announced new data on 22 patients, with follow-up of at least three months, and ranging from four months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment. CTX001 is being investigated in two ongoing Phase 1/2 clinical trials as a potential one-time therapy for patients suffering from transfusion-dependent beta thalassemia, or TDT, and severe sickle cell disease , or SCD. In total, more than 40 patients have been dosed across both studies to date. All 15 patients with TDT, including six who have the beta zero/beta zero or other severe genotypes, were transfusion-free at last follow-up, and all seven patients with severe SCD were free of vaso-occlusive crises, or VOCs, from CTX001 infusion through last follow-up. Five patients with TDT and two patients with SCD now have follow-up of greater than one year, demonstrating a stable and durable response to treatment. These data are available as e-posters beginning on June 11. The 15 patients with TDT reported at EHA are patients who had reached at least three months of follow-up after CTX001 dosing and therefore could be assessed for initial safety and efficacy. All 15 patients showed a similar pattern of response, with rapid and sustained increases in total hemoglobin, fetal hemoglobin and transfusion independence. All 15 patients were transfusion independent with follow-up ranging from 4 to 26 months after CTX001 infusion and had clinically meaningful improvements in total hemoglobin from 8.9 to 16.9 g/dL and fetal hemoglobin from 67.3% to 99.6% at last visit. The seven patients reported at EHA are patients who had reached at least three months of follow-up after CTX001 dosing and therefore could be assessed for initial safety and efficacy. All seven patients showed a similar pattern of response, with rapid and sustained increases in total hemoglobin and fetal hemoglobin, as well as elimination of VOCs. All seven patients remained VOC-free with follow-up ranging from five to 22 months after CTX001 infusion and had clinically meaningful improvements in total hemoglobin from 11 to 15.9 g/dL and fetal hemoglobin levels from 39.6% to 49.6% at last visit. Enrollment and dosing are ongoing.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$216.92 /

+3.43 (+1.61%)

CRSP Crispr Therapeutics
$123.67 /

+3.69 (+3.08%)

VRTX Vertex Pharmaceuticals
$216.92 /

+3.43 (+1.61%)

06/11/21 Daiwa
Vertex Pharmaceuticals downgraded to Neutral from Outperform at Daiwa
06/11/21 Piper Sandler
Vertex cystic fibrosis franchise remains strong, says Piper Sandler
04/21/21 Jefferies
Jefferies upgrades Crispr Therapeutics to Buy after Vertex deal renegotiated
04/21/21 Barclays
Crispr Therapeutics price target raised to $160 from $140 at Barclays
CRSP Crispr Therapeutics
$123.67 /

+3.69 (+3.08%)

05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
04/21/21 Jefferies
Crispr Therapeutics upgraded to Buy from Hold at Jefferies
VRTX Vertex Pharmaceuticals
$216.92 /

+3.43 (+1.61%)

CRSP Crispr Therapeutics
$123.67 /

+3.69 (+3.08%)

  • 01
    Jul
VRTX Vertex Pharmaceuticals
$216.92 /

+3.43 (+1.61%)

VRTX Vertex Pharmaceuticals
$216.92 /

+3.43 (+1.61%)

VRTX Vertex Pharmaceuticals
$216.92 /

+3.43 (+1.61%)

CRSP Crispr Therapeutics
$123.67 /

+3.69 (+3.08%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
06/04/21
06/04
04:55
06/04/21
04:55
VERU

Veru

$8.84 /

-0.29 (-3.18%)

, CABA

Cabaletta Bio

$10.20 /

-0.05 (-0.49%)

, ICLR

Icon

$220.43 /

-0.04 (-0.02%)

, PRTA

Prothena

$28.65 /

+0.48 (+1.70%)

, SHC

Sotera Health

$24.47 /

+0.04 (+0.16%)

, PHAT

Phathom Pharmaceuticals

$33.20 /

+0.41 (+1.25%)

, CCCC

C4 Therapeutics

$38.13 /

+0.2 (+0.53%)

, LABP

Landos Biopharma

$11.81 /

+0.53 (+4.70%)

, TWST

Twist Bioscience

$96.05 /

-6.22 (-6.08%)

, LVTX

Lava Therapeutics

$11.04 /

+0.05 (+0.45%)

, ACRS

Aclaris Therapeutics

$21.93 /

+0.28 (+1.29%)

, CRSP

Crispr Therapeutics

$109.92 /

-4.79 (-4.18%)

, GILD

Gilead

$66.48 /

+0.44 (+0.67%)

, A

Agilent

$136.40 /

-0.175 (-0.13%)

, ICAD

iCAD

$17.10 /

+0.38 (+2.27%)

, CRIS

Curis

$14.46 /

+0.02 (+0.14%)

, ADUS

Addus HomeCare

$94.40 /

-0.53 (-0.56%)

, VOR

Vor Biopharma

$19.95 /

+0.4 (+2.05%)

, VCNX

Vaccinex

$2.33 /

-0.14 (-5.67%)

2021 Global Healthcare…

2021 Global Healthcare Virtual Conference to be held on June 1-4.

ShowHide Related Items >><<
VOR Vor Biopharma
$19.95 /

+0.4 (+2.05%)

VERU Veru
$8.84 /

-0.29 (-3.18%)

VCNX Vaccinex
$2.33 /

-0.14 (-5.67%)

TWST Twist Bioscience
$96.05 /

-6.22 (-6.08%)

SHC Sotera Health
$24.47 /

+0.04 (+0.16%)

PRTA Prothena
$28.65 /

+0.48 (+1.70%)

PHAT Phathom Pharmaceuticals
$33.20 /

+0.41 (+1.25%)

LVTX Lava Therapeutics
$11.04 /

+0.05 (+0.45%)

LABP Landos Biopharma
$11.81 /

+0.53 (+4.70%)

ICLR Icon
$220.43 /

-0.04 (-0.02%)

ICAD iCAD
$17.10 /

+0.38 (+2.27%)

GILD Gilead
$66.48 /

+0.44 (+0.67%)

CRSP Crispr Therapeutics
$109.92 /

-4.79 (-4.18%)

CRIS Curis
$14.46 /

+0.02 (+0.14%)

CCCC C4 Therapeutics
$38.13 /

+0.2 (+0.53%)

CABA Cabaletta Bio
$10.20 /

-0.05 (-0.49%)

ADUS Addus HomeCare
$94.40 /

-0.53 (-0.56%)

ACRS Aclaris Therapeutics
$21.93 /

+0.28 (+1.29%)

A Agilent
$136.40 /

-0.175 (-0.13%)

VERU Veru
$8.84 /

-0.29 (-3.18%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
CABA Cabaletta Bio
$10.20 /

-0.05 (-0.49%)

03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
ICLR Icon
$220.43 /

-0.04 (-0.02%)

05/10/21 Truist
PRA Health downgraded to Hold from Buy at Truist
05/03/21 Mizuho
Icon price target raised to $242 from $217 at Mizuho
04/29/21 Credit Suisse
Icon price target raised to $245 from $240 at Credit Suisse
04/20/21 Baird
PRA Health downgraded to Neutral from Outperform at Baird
PRTA Prothena
$28.65 /

+0.48 (+1.70%)

06/01/21 Oppenheimer
Prothena price target raised to $45 from $40 at Oppenheimer
05/26/21
Fly Intel: Top five analyst initiations
05/26/21 Citi
Prothena initiated with a Buy at Citi
05/12/21 Oppenheimer
Prothena price target raised to $40 from $35 at Oppenheimer
SHC Sotera Health
$24.47 /

+0.04 (+0.16%)

05/14/21 Barclays
Sotera Health price target lowered to $29 from $35 at Barclays
05/14/21 Citi
Sotera Health selloff brings attractive entry point, says Citi
03/02/21 Barclays
Sotera Health initiated with an Overweight at Barclays
03/02/21 Barclays
Sotera Health initiated with an Overweight at Barclays
PHAT Phathom Pharmaceuticals
$33.20 /

+0.41 (+1.25%)

05/12/21 Goldman Sachs
Phathom Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
02/17/21 BMO Capital
Phathom Pharmaceuticals initiated with an Outperform at BMO Capital
02/02/21 Guggenheim
Phathom Pharmaceuticals initiated with a Buy at Guggenheim
01/28/21
Fly Intel: Top five analyst initiations
CCCC C4 Therapeutics
$38.13 /

+0.2 (+0.53%)

03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
10/28/20 UBS
C4 Therapeutics initiated with a Buy at UBS
LABP Landos Biopharma
$11.81 /

+0.53 (+4.70%)

03/01/21 Jefferies
Landos Biopharma initiated with a Buy at Jefferies
03/01/21 JPMorgan
Landos Biopharma initiated with a Neutral at JPMorgan
03/01/21 Raymond James
Landos Biopharma initiated with an Outperform at Raymond James
03/01/21 SVB Leerink
Landos Biopharma initiated with an Outperform at SVB Leerink
TWST Twist Bioscience
$96.05 /

-6.22 (-6.08%)

05/11/21 Piper Sandler
Twist Bioscience recent weakness a buying opportunity, says Piper Sandler
04/12/21
Fly Intel: Top five analyst initiations
04/12/21 Piper Sandler
Twist Bioscience initiated with an Overweight at Piper Sandler
02/05/21 Baird
Twist Bioscience price target raised to $200 from $125 at Baird
LVTX Lava Therapeutics
$11.04 /

+0.05 (+0.45%)

04/19/21 SVB Leerink
SVB Leerink bullish on Lava Therapeutics, initiates with an Outperform
04/19/21 JPMorgan
Lava Therapeutics initiated with an Overweight at JPMorgan
04/19/21 Jefferies
Lava Therapeutics initiated with a Buy at Jefferies
04/19/21 SVB Leerink
Lava Therapeutics initiated with an Outperform at SVB Leerink
ACRS Aclaris Therapeutics
$21.93 /

+0.28 (+1.29%)

04/21/21 H.C. Wainwright
Aclaris Therapeutics initiated with a Buy at H.C. Wainwright
03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
CRSP Crispr Therapeutics
$109.92 /

-4.79 (-4.18%)

05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
04/21/21 Jefferies
Jefferies upgrades Crispr Therapeutics to Buy after Vertex deal renegotiated
04/21/21 Barclays
Crispr Therapeutics price target raised to $160 from $140 at Barclays
04/21/21 Jefferies
Crispr Therapeutics upgraded to Buy from Hold at Jefferies
GILD Gilead
$66.48 /

+0.44 (+0.67%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
A Agilent
$136.40 /

-0.175 (-0.13%)

05/26/21 SVB Leerink
Agilent price target raised to $145 from $140 at SVB Leerink
05/26/21 KeyBanc
Agilent price target raised to $157 from $148 at KeyBanc
05/26/21 Wells Fargo
Agilent price target raised to $150 from $140 at Wells Fargo
05/26/21 Baird
Agilent price target raised to $144 from $137 at Baird
ICAD iCAD
$17.10 /

+0.38 (+2.27%)

04/22/21 Guggenheim
iCAD initiated with a Buy at Guggenheim
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
CRIS Curis
$14.46 /

+0.02 (+0.14%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
ADUS Addus HomeCare
$94.40 /

-0.53 (-0.56%)

08/12/20 BMO Capital
Addus HomeCare price target raised to $115 from $103 at BMO Capital
08/11/20 Oppenheimer
Addus HomeCare price target raised to $115 from $107 at Oppenheimer
06/17/20 Baird
Addus HomeCare price target raised to $100 from $96 at Baird
VOR Vor Biopharma
$19.95 /

+0.4 (+2.05%)

03/25/21 B. Riley
Vor Biopharma initiated with a Buy at B. Riley Securities
03/02/21 Evercore ISI
Vor Biopharma initiated with an Outperform at Evercore ISI
03/02/21 Stifel
Vor Biopharma initiated with a Buy at Stifel
03/02/21 Goldman Sachs
Vor Biopharma initiated with a Sell at Goldman Sachs
VCNX Vaccinex
$2.33 /

-0.14 (-5.67%)

09/25/20 Oppenheimer
Vaccinex price target lowered to $7 from $22 at Oppenheimer
09/22/20 BTIG
Vaccinex downgraded to Neutral from Buy at BTIG
VOR Vor Biopharma
$19.95 /

+0.4 (+2.05%)

VERU Veru
$8.84 /

-0.29 (-3.18%)

VCNX Vaccinex
$2.33 /

-0.14 (-5.67%)

TWST Twist Bioscience
$96.05 /

-6.22 (-6.08%)

SHC Sotera Health
$24.47 /

+0.04 (+0.16%)

PRTA Prothena
$28.65 /

+0.48 (+1.70%)

PHAT Phathom Pharmaceuticals
$33.20 /

+0.41 (+1.25%)

LVTX Lava Therapeutics
$11.04 /

+0.05 (+0.45%)

LABP Landos Biopharma
$11.81 /

+0.53 (+4.70%)

ICLR Icon
$220.43 /

-0.04 (-0.02%)

ICAD iCAD
$17.10 /

+0.38 (+2.27%)

GILD Gilead
$66.48 /

+0.44 (+0.67%)

CRSP Crispr Therapeutics
$109.92 /

-4.79 (-4.18%)

CRIS Curis
$14.46 /

+0.02 (+0.14%)

CABA Cabaletta Bio
$10.20 /

-0.05 (-0.49%)

ADUS Addus HomeCare
$94.40 /

-0.53 (-0.56%)

ACRS Aclaris Therapeutics
$21.93 /

+0.28 (+1.29%)

A Agilent
$136.40 /

-0.175 (-0.13%)

  • 24
    Mar
  • 25
    Mar
  • 18
    Mar
  • 03
    Mar
  • 18
    Feb
  • 05
    Feb
  • 04
    Feb
  • 20
    Jan
  • 17
    Dec
  • 09
    Dec
  • 08
    Dec
  • 03
    Dec
  • 20
    Nov
  • 02
    Oct
  • 13
    Aug
  • 01
    Jul
ICLR Icon
$220.43 /

-0.04 (-0.02%)

GILD Gilead
$66.48 /

+0.44 (+0.67%)

VERU Veru
$8.84 /

-0.29 (-3.18%)

TWST Twist Bioscience
$96.05 /

-6.22 (-6.08%)

PRTA Prothena
$28.65 /

+0.48 (+1.70%)

PHAT Phathom Pharmaceuticals
$33.20 /

+0.41 (+1.25%)

LVTX Lava Therapeutics
$11.04 /

+0.05 (+0.45%)

LABP Landos Biopharma
$11.81 /

+0.53 (+4.70%)

ICLR Icon
$220.43 /

-0.04 (-0.02%)

ICAD iCAD
$17.10 /

+0.38 (+2.27%)

GILD Gilead
$66.48 /

+0.44 (+0.67%)

CRSP Crispr Therapeutics
$109.92 /

-4.79 (-4.18%)

CRIS Curis
$14.46 /

+0.02 (+0.14%)

ADUS Addus HomeCare
$94.40 /

-0.53 (-0.56%)

ACRS Aclaris Therapeutics
$21.93 /

+0.28 (+1.29%)

A Agilent
$136.40 /

-0.175 (-0.13%)

VERU Veru
$8.84 /

-0.29 (-3.18%)

VCNX Vaccinex
$2.33 /

-0.14 (-5.67%)

SHC Sotera Health
$24.47 /

+0.04 (+0.16%)

GILD Gilead
$66.48 /

+0.44 (+0.67%)

CRSP Crispr Therapeutics
$109.92 /

-4.79 (-4.18%)

CRIS Curis
$14.46 /

+0.02 (+0.14%)

CCCC C4 Therapeutics
$38.13 /

+0.2 (+0.53%)

CABA Cabaletta Bio
$10.20 /

-0.05 (-0.49%)

A Agilent
$136.40 /

-0.175 (-0.13%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
06/03/21
06/03
04:55
06/03/21
04:55
VERU

Veru

$9.12 /

+0.25 (+2.82%)

, CABA

Cabaletta Bio

$10.29 /

-0.77 (-6.96%)

, ICLR

Icon

$220.53 /

-2.16 (-0.97%)

, PRTA

Prothena

$28.17 /

+0.83 (+3.04%)

, SHC

Sotera Health

$24.44 /

+0.13 (+0.53%)

, PHAT

Phathom Pharmaceuticals

$32.70 /

-3.57 (-9.84%)

, CCCC

C4 Therapeutics

$38.02 /

+0.51 (+1.36%)

, LABP

Landos Biopharma

$11.32 /

+0.22 (+1.98%)

, TWST

Twist Bioscience

$102.42 /

-3.45 (-3.26%)

, LVTX

Lava Therapeutics

$10.90 /

-0.12 (-1.09%)

, ACRS

Aclaris Therapeutics

$21.76 /

-1.88 (-7.95%)

, CRSP

Crispr Therapeutics

$114.73 /

-1.02 (-0.88%)

, GILD

Gilead

$66.04 /

+0.73 (+1.12%)

, A

Agilent

$136.58 /

-0.665 (-0.48%)

, ICAD

iCAD

$16.72 /

+0.09 (+0.54%)

, CRIS

Curis

$14.44 /

+0.01 (+0.07%)

, ADUS

Addus HomeCare

$95.26 /

+0.1 (+0.11%)

, VOR

Vor Biopharma

$19.72 /

-0.8 (-3.90%)

, VCNX

Vaccinex

$2.47 /

+0.03 (+1.23%)

2021 Global Healthcare…

2021 Global Healthcare Virtual Conference to be held on June 1-4.

ShowHide Related Items >><<
VOR Vor Biopharma
$19.72 /

-0.8 (-3.90%)

VERU Veru
$9.12 /

+0.25 (+2.82%)

VCNX Vaccinex
$2.47 /

+0.03 (+1.23%)

TWST Twist Bioscience
$102.42 /

-3.45 (-3.26%)

SHC Sotera Health
$24.44 /

+0.13 (+0.53%)

PRTA Prothena
$28.17 /

+0.83 (+3.04%)

PHAT Phathom Pharmaceuticals
$32.70 /

-3.57 (-9.84%)

LVTX Lava Therapeutics
$10.90 /

-0.12 (-1.09%)

LABP Landos Biopharma
$11.32 /

+0.22 (+1.98%)

ICLR Icon
$220.53 /

-2.16 (-0.97%)

ICAD iCAD
$16.72 /

+0.09 (+0.54%)

GILD Gilead
$66.04 /

+0.73 (+1.12%)

CRSP Crispr Therapeutics
$114.73 /

-1.02 (-0.88%)

CRIS Curis
$14.44 /

+0.01 (+0.07%)

CCCC C4 Therapeutics
$38.02 /

+0.51 (+1.36%)

CABA Cabaletta Bio
$10.29 /

-0.77 (-6.96%)

ADUS Addus HomeCare
$95.26 /

+0.1 (+0.11%)

ACRS Aclaris Therapeutics
$21.76 /

-1.88 (-7.95%)

A Agilent
$136.58 /

-0.665 (-0.48%)

VERU Veru
$9.12 /

+0.25 (+2.82%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
CABA Cabaletta Bio
$10.29 /

-0.77 (-6.96%)

03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
ICLR Icon
$220.53 /

-2.16 (-0.97%)

05/10/21 Truist
PRA Health downgraded to Hold from Buy at Truist
05/03/21 Mizuho
Icon price target raised to $242 from $217 at Mizuho
04/29/21 Credit Suisse
Icon price target raised to $245 from $240 at Credit Suisse
04/20/21 Baird
PRA Health downgraded to Neutral from Outperform at Baird
PRTA Prothena
$28.17 /

+0.83 (+3.04%)

06/01/21 Oppenheimer
Prothena price target raised to $45 from $40 at Oppenheimer
05/26/21
Fly Intel: Top five analyst initiations
05/26/21 Citi
Prothena initiated with a Buy at Citi
05/12/21 Oppenheimer
Prothena price target raised to $40 from $35 at Oppenheimer
SHC Sotera Health
$24.44 /

+0.13 (+0.53%)

05/14/21 Barclays
Sotera Health price target lowered to $29 from $35 at Barclays
05/14/21 Citi
Sotera Health selloff brings attractive entry point, says Citi
03/02/21 Barclays
Sotera Health initiated with an Overweight at Barclays
03/02/21 Barclays
Sotera Health initiated with an Overweight at Barclays
PHAT Phathom Pharmaceuticals
$32.70 /

-3.57 (-9.84%)

05/12/21 Goldman Sachs
Phathom Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
02/17/21 BMO Capital
Phathom Pharmaceuticals initiated with an Outperform at BMO Capital
02/02/21 Guggenheim
Phathom Pharmaceuticals initiated with a Buy at Guggenheim
01/28/21
Fly Intel: Top five analyst initiations
CCCC C4 Therapeutics
$38.02 /

+0.51 (+1.36%)

03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
10/28/20 UBS
C4 Therapeutics initiated with a Buy at UBS
LABP Landos Biopharma
$11.32 /

+0.22 (+1.98%)

03/01/21 Jefferies
Landos Biopharma initiated with a Buy at Jefferies
03/01/21 JPMorgan
Landos Biopharma initiated with a Neutral at JPMorgan
03/01/21 Raymond James
Landos Biopharma initiated with an Outperform at Raymond James
03/01/21 SVB Leerink
Landos Biopharma initiated with an Outperform at SVB Leerink
TWST Twist Bioscience
$102.42 /

-3.45 (-3.26%)

05/11/21 Piper Sandler
Twist Bioscience recent weakness a buying opportunity, says Piper Sandler
04/12/21
Fly Intel: Top five analyst initiations
04/12/21 Piper Sandler
Twist Bioscience initiated with an Overweight at Piper Sandler
02/05/21 Baird
Twist Bioscience price target raised to $200 from $125 at Baird
LVTX Lava Therapeutics
$10.90 /

-0.12 (-1.09%)

04/19/21 SVB Leerink
SVB Leerink bullish on Lava Therapeutics, initiates with an Outperform
04/19/21 JPMorgan
Lava Therapeutics initiated with an Overweight at JPMorgan
04/19/21 Jefferies
Lava Therapeutics initiated with a Buy at Jefferies
04/19/21 SVB Leerink
Lava Therapeutics initiated with an Outperform at SVB Leerink
ACRS Aclaris Therapeutics
$21.76 /

-1.88 (-7.95%)

04/21/21 H.C. Wainwright
Aclaris Therapeutics initiated with a Buy at H.C. Wainwright
03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
CRSP Crispr Therapeutics
$114.73 /

-1.02 (-0.88%)

05/13/21 Evercore ISI
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
04/21/21 Jefferies
Jefferies upgrades Crispr Therapeutics to Buy after Vertex deal renegotiated
04/21/21 Barclays
Crispr Therapeutics price target raised to $160 from $140 at Barclays
04/21/21 Jefferies
Crispr Therapeutics upgraded to Buy from Hold at Jefferies
GILD Gilead
$66.04 /

+0.73 (+1.12%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
A Agilent
$136.58 /

-0.665 (-0.48%)

05/26/21 SVB Leerink
Agilent price target raised to $145 from $140 at SVB Leerink
05/26/21 KeyBanc
Agilent price target raised to $157 from $148 at KeyBanc
05/26/21 Wells Fargo
Agilent price target raised to $150 from $140 at Wells Fargo
05/26/21 Baird
Agilent price target raised to $144 from $137 at Baird
ICAD iCAD
$16.72 /

+0.09 (+0.54%)

04/22/21 Guggenheim
iCAD initiated with a Buy at Guggenheim
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
03/23/21 BTIG
iCAD initiated with a Buy at BTIG
02/26/21 B. Riley
iCAD price target raised to $23 from $18 at B. Riley Securities
CRIS Curis
$14.44 /

+0.01 (+0.07%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
ADUS Addus HomeCare
$95.26 /

+0.1 (+0.11%)

08/12/20 BMO Capital
Addus HomeCare price target raised to $115 from $103 at BMO Capital
08/11/20 Oppenheimer
Addus HomeCare price target raised to $115 from $107 at Oppenheimer
06/17/20 Baird
Addus HomeCare price target raised to $100 from $96 at Baird
VOR Vor Biopharma
$19.72 /

-0.8 (-3.90%)

03/25/21 B. Riley
Vor Biopharma initiated with a Buy at B. Riley Securities
03/02/21 Evercore ISI
Vor Biopharma initiated with an Outperform at Evercore ISI
03/02/21 Stifel
Vor Biopharma initiated with a Buy at Stifel
03/02/21 Goldman Sachs
Vor Biopharma initiated with a Sell at Goldman Sachs
VCNX Vaccinex
$2.47 /

+0.03 (+1.23%)

09/25/20 Oppenheimer
Vaccinex price target lowered to $7 from $22 at Oppenheimer
09/22/20 BTIG
Vaccinex downgraded to Neutral from Buy at BTIG
VOR Vor Biopharma
$19.72 /

-0.8 (-3.90%)

VERU Veru
$9.12 /

+0.25 (+2.82%)

VCNX Vaccinex
$2.47 /

+0.03 (+1.23%)

TWST Twist Bioscience
$102.42 /

-3.45 (-3.26%)

SHC Sotera Health
$24.44 /

+0.13 (+0.53%)

PRTA Prothena
$28.17 /

+0.83 (+3.04%)

PHAT Phathom Pharmaceuticals
$32.70 /

-3.57 (-9.84%)

LVTX Lava Therapeutics
$10.90 /

-0.12 (-1.09%)

LABP Landos Biopharma
$11.32 /

+0.22 (+1.98%)

ICLR Icon
$220.53 /

-2.16 (-0.97%)

ICAD iCAD
$16.72 /

+0.09 (+0.54%)

GILD Gilead
$66.04 /

+0.73 (+1.12%)

CRSP Crispr Therapeutics
$114.73 /

-1.02 (-0.88%)

CRIS Curis
$14.44 /

+0.01 (+0.07%)

CABA Cabaletta Bio
$10.29 /

-0.77 (-6.96%)

ADUS Addus HomeCare
$95.26 /

+0.1 (+0.11%)

ACRS Aclaris Therapeutics
$21.76 /

-1.88 (-7.95%)

A Agilent
$136.58 /

-0.665 (-0.48%)

  • 24
    Mar
  • 25
    Mar
  • 18
    Mar
  • 03
    Mar
  • 18
    Feb
  • 05
    Feb
  • 04
    Feb
  • 20
    Jan
  • 17
    Dec
  • 09
    Dec
  • 08
    Dec
  • 03
    Dec
  • 20
    Nov
  • 02
    Oct
  • 13
    Aug
  • 01
    Jul
  • 04
    Jun
ICLR Icon
$220.53 /

-2.16 (-0.97%)

GILD Gilead
$66.04 /

+0.73 (+1.12%)

VERU Veru
$9.12 /

+0.25 (+2.82%)

TWST Twist Bioscience
$102.42 /

-3.45 (-3.26%)

PRTA Prothena
$28.17 /

+0.83 (+3.04%)

PHAT Phathom Pharmaceuticals
$32.70 /

-3.57 (-9.84%)

LVTX Lava Therapeutics
$10.90 /

-0.12 (-1.09%)

LABP Landos Biopharma
$11.32 /

+0.22 (+1.98%)

ICLR Icon
$220.53 /

-2.16 (-0.97%)

ICAD iCAD
$16.72 /

+0.09 (+0.54%)

GILD Gilead
$66.04 /

+0.73 (+1.12%)

CRSP Crispr Therapeutics
$114.73 /

-1.02 (-0.88%)

CRIS Curis
$14.44 /

+0.01 (+0.07%)

ADUS Addus HomeCare
$95.26 /

+0.1 (+0.11%)

ACRS Aclaris Therapeutics
$21.76 /

-1.88 (-7.95%)

A Agilent
$136.58 /

-0.665 (-0.48%)

VERU Veru
$9.12 /

+0.25 (+2.82%)

VCNX Vaccinex
$2.47 /

+0.03 (+1.23%)

SHC Sotera Health
$24.44 /

+0.13 (+0.53%)

GILD Gilead
$66.04 /

+0.73 (+1.12%)

CRSP Crispr Therapeutics
$114.73 /

-1.02 (-0.88%)

CRIS Curis
$14.44 /

+0.01 (+0.07%)

CCCC C4 Therapeutics
$38.02 /

+0.51 (+1.36%)

CABA Cabaletta Bio
$10.29 /

-0.77 (-6.96%)

A Agilent
$136.58 /

-0.665 (-0.48%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.